Our Peptide-siRNA research teams, delivery platform developers, and academic laboratories working on RNAi programs that require chemically defined peptide-enabled siRNA constructs. Peptide-siRNA conjugates are used when teams need more than standard duplex synthesis alone, such as improved cellular uptake, receptor-directed targeting, endosomal escape support, or cleaner structure-activity relationships than loosely assembled peptide/siRNA complexes. Successful program execution depends on how well the siRNA sequence, peptide class, attachment site, linker design, purification strategy, and downstream assay plan are coordinated from the start.
Our platform combines siRNA design, peptide selection, site-defined conjugation, analytical characterization, and application-focused development planning to help clients build research-ready conjugates with clear composition and practical usability. By integrating oligonucleotide chemistry with peptide engineering and delivery-aware design logic, we help reduce construct heterogeneity, avoid avoidable strand-function losses, and generate peptide-siRNA candidates that are better aligned with demanding discovery and nonclinical evaluation workflows.
Poor Cellular Entry: Free siRNA is highly anionic and often shows limited membrane passage in many relevant research models. Peptide conjugation is typically explored when teams need a more direct way to introduce uptake-promoting or targeting functionality into the construct itself rather than relying only on an external carrier.
Unproductive Uptake: Internalization alone does not guarantee silencing. Many peptide-siRNA projects stall because material enters cells but remains trapped in endosomal compartments. We support peptide class selection, spacer planning, and linker decisions that are aligned with the need for productive intracellular delivery rather than uptake signal alone.
Loss of RNAi Activity After Conjugation: Attachment position, steric load, and siRNA architecture can reduce guide-strand performance if they are not planned carefully. We review strand orientation, terminal modification strategy, and conjugation site selection to preserve silencing function while still enabling peptide-driven delivery behavior.
Conjugate Heterogeneity and Purification Burden: Peptide-siRNA products can become difficult to characterize when multiple reactive sites or poorly controlled linker chemistries are used. Our services focus on site-defined handle installation, fit-for-purpose purification, and analytical confirmation so that clients receive structurally interpretable materials rather than mixed populations.
Mismatch Between Construct Design and Delivery Workflow: A peptide-siRNA format that works for one cell model, target class, or assay format may fail in another. Our RNA Drug Delivery System capabilities support practical assessment of whether a stand-alone conjugate is suitable, whether a cleavable design is preferable, or whether the construct should be paired with a broader delivery workflow for research-stage studies.
Our peptide-siRNA conjugate services are designed for teams that need one coordinated workflow across siRNA architecture, peptide engineering, linker chemistry, purification, and analytical review. We support chemically defined constructs for uptake studies, receptor-targeting concepts, intracellular trafficking work, mechanism-focused RNAi programs, and nonclinical delivery optimization.
Whether the project starts from an existing siRNA sequence, a known peptide shuttle, or a new conjugate concept, we tailor the build strategy to the actual technical question being asked: preserve knockdown, improve cell entry, compare peptide classes, test cleavable release, or establish a reproducible lead format for broader screening.
The table below helps research teams compare common peptide-siRNA construct strategies and identify which format best fits their uptake, targeting, release, and analytical objectives.
| Construct Strategy | Best Used For | Main Design Features | Primary Watchpoints | Typical Service Focus |
| CPP-siRNA Conjugate | Improving entry into uptake-limited or hard-to-transfect cell models | Cationic or amphipathic peptide, defined attachment site, spacer to reduce steric burden | Aggregation, nonproductive uptake, endosomal trapping, sequence-dependent assay variability | Peptide selection, conjugation optimization, uptake and knockdown comparison |
| Targeting Peptide-siRNA Conjugate | Receptor-mediated uptake and cell-type-selective research workflows | Ligand peptide with preserved binding motif, controlled linker orientation, siRNA duplex matched to target study | Receptor dependence, steric masking of peptide function, target-model mismatch | Ligand review, orientation planning, screening in receptor-relevant systems |
| Endosomolytic Peptide-siRNA Conjugate | Projects where internalization is achievable but cytosolic delivery remains weak | pH-responsive or membrane-active peptide elements combined with a functional siRNA scaffold | Membrane perturbation, sequence-specific tolerability, difficult activity interpretation without controls | Peptide engineering, release logic, functional delivery-focused assay design |
| Cleavable Peptide-siRNA Conjugate | Intracellular release studies where the peptide should assist delivery but not remain permanently attached | Redox- or otherwise trigger-responsive linker inserted between peptide and siRNA | Premature cleavage, incomplete release, purification complexity, stability testing burden | Linker selection, release-oriented analytics, side-by-side construct comparison |
| Non-cleavable Tracking Conjugate | Mechanistic trafficking studies and construct-distribution analysis | Stable linker, robust structural integrity, often combined with labeled or reporter-ready formats | Reduced silencing if linker or peptide remains sterically disruptive | Stable conjugation chemistry, purity control, analytical consistency |
| Peptide-siRNA Plus Carrier | Research programs testing whether a defined conjugate still benefits from a secondary delivery system | Chemically defined conjugate paired with lipid, polymer, or nanoparticle workflow | Added formulation complexity, harder attribution of performance effects, broader QC requirements | Conjugate build plus formulation feasibility review and development planning |
Peptide-siRNA conjugate success usually depends on controlling a small set of design variables early. This matrix summarizes the most important technical checkpoints that influence whether a construct remains interpretable, manufacturable, and functionally useful.
| Development Parameter | Why It Matters | Typical Review Criteria | Project Stage | Client Value |
| Attachment Site | Conjugation position can preserve or reduce guide-strand function | Sense versus antisense placement, 3′/5′ orientation, steric load near functional ends | Early Design | Reduces avoidable activity loss before synthesis begins |
| siRNA Stabilization Pattern | Duplex durability and RISC compatibility must remain balanced | Terminal protection, modification density, strand asymmetry, overhang logic | Early Design | Supports better construct longevity without overengineering the duplex |
| Peptide Physicochemical Profile | Charge and hydrophobicity influence binding, uptake, aggregation, and handling | Sequence composition, amphipathicity, peptide length, expected solubility | Design / Feasibility | Improves candidate selection before expensive build cycles |
| Linker Architecture | Linker chemistry determines structural stability, release behavior, and analytical tractability | Cleavable versus stable, spacer length, polarity, compatibility with chosen handles | Feasibility / Build | Aligns chemistry choice with actual delivery and assay goals |
| Purification Strategy | Inadequate cleanup can leave free peptide or free siRNA that distorts biological readouts | Separation challenge, impurity profile, target purity level, material recovery | Build / QC | Increases confidence that observed performance comes from the intended conjugate |
| Analytical Confirmation | Conjugates need more than basic oligo release checks to confirm identity and composition | Mass confirmation, chromatographic purity, UV profile, gel-based support where useful | QC / Release | Provides a clearer basis for internal go/no-go decisions |
| Delivery Readout Strategy | Uptake and silencing are not interchangeable endpoints | Internalization assay, trafficking readout, target knockdown plan, construct controls | Screening | Helps clients interpret why a build succeeds or fails |
| Rebuild Logic | Most peptide-siRNA programs require structured iteration rather than one-shot optimization | Which variable changes first: peptide, linker, strand orientation, spacer, or duplex chemistry | Post-Screening | Makes follow-up rounds faster and more technically focused |
Our workflow is built for discovery and nonclinical programs that need clear technical control from construct concept to purified material and analytical handoff. Each step is structured to reduce ambiguity in conjugate architecture and improve the usefulness of screening data.
We define the target gene, intended cell or assay context, peptide function, preferred delivery hypothesis, and expected deliverables. This step clarifies whether the program is centered on uptake enhancement, receptor targeting, endosomal escape, mechanistic comparison, or broader siRNA lead optimization.
We evaluate siRNA strand design, peptide class, attachment position, functional handles, and linker type before chemistry begins. The output is a build plan that matches the client's technical question rather than defaulting to a generic peptide-siRNA format.
The siRNA and peptide components are prepared with the required terminal or side-chain functionalities for controlled coupling. At this stage, we also align purity targets and processing decisions with whether the project is a feasibility build, a screening panel, or a more advanced research lot.
Site-defined coupling is carried out using the selected chemistry under conditions matched to RNA and peptide stability. Unreacted components and side products are then removed using fit-for-purpose purification methods to obtain analytically interpretable conjugate material.
We confirm identity, assess purity, and organize the analytical package around the intended downstream use. Where required, we help structure comparative screening plans so clients can evaluate uptake, trafficking, and silencing behavior in a way that distinguishes productive delivery from simple internalization.
Final materials and project data are delivered in a format that supports internal R&D review and follow-on design decisions. If optimization is needed, we map the next iteration logically by prioritizing the variable most likely to improve performance, such as peptide class, linker type, spacer length, or conjugation orientation.
Peptide-siRNA conjugates require more than routine oligonucleotide synthesis or standard peptide coupling. Clients choose our platform when they need the siRNA, peptide, and conjugation strategy to be designed as one system, with realistic attention to RNAi function, delivery behavior, analytical tractability, and follow-on optimization.
Peptide-siRNA conjugates are valuable across RNAi research, delivery mechanism studies, and nonclinical lead optimization when teams need chemically defined constructs that combine gene silencing with uptake or targeting functionality. Our services support both focused build requests and broader conjugate evaluation programs.
Whether you need a new peptide-siRNA construct, a comparative conjugate panel, a cleavable linker design, or a broader RNAi delivery feasibility study, our team can help you build a program around the variables that matter most. We support research and nonclinical projects with coordinated siRNA design, peptide selection, conjugation strategy development, purification, analytical review, and follow-on optimization planning. From early feasibility work to larger research-use builds, our services are designed to help clients generate peptide-siRNA conjugates that are structurally clear, experimentally useful, and easier to advance into the next stage of evaluation. Contact Us to discuss your peptide-siRNA conjugate requirements.
CPPs enable efficient cellular uptake through multiple internalization pathways, enhance endosomal escape, and provide versatile conjugation options while maintaining siRNA functionality across diverse cell types.
CPPs are classified into hydrophilic, amphiphilic, targeting ligand-conjugated, and activatable categories, with selection based on target cell permeability, endosomal escape efficiency, and cargo compatibility requirements.
Strategic attachment at the 5'-internal or 3'-terminus of siRNA using optimized linker chemistry preserves RNA-induced silencing complex formation and gene targeting capability.
Amphiphilic CPPs combine hydrophobic and hydrophilic domains that facilitate membrane interaction, promote endosomal disruption, and improve cytoplasmic release of conjugated siRNA molecules.
Loading ......
